Streetbeat News

Earnings

VST

Vistra has reaffirmed its financial guidance for FY24, maintaining its expected ranges for Adjusted EBITDA ($3,700 - $4,100 million) and Adjusted Free Cash Flow before Growth (FCFbG) ($1,900 - $2,300 million).

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:03 pm

NRG

NRG Energy reported Q4 sales of $6.77 billion, surpassing the analyst consensus estimate of $6.40 billion by 5.76%. However, this represents a 13.85% decrease from the $7.86 billion sales reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:03 pm

NOVT

Novanta reported Q4 adjusted EPS of $0.63, meeting analyst estimates, with a 16% decrease from last year's $0.75. Sales were $211.57M, slightly above the $210.69M estimate but down 3.12% from last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:03 pm

FLGT

Fulgent Genetics reported its Q4 adjusted EPS at $0.28, which may not be directly comparable to the estimated $(0.29). The company's sales of $70.50M exceeded the estimated $66.32M.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:02 pm

VST

Vistra announced its FY24 financial results, reporting a net income of $1.492 billion and a cash flow from operations of $5.453 billion.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:02 pm

DIBS

1stdibs.com (NASDAQ:DIBS) reported Q4 2023 earnings with a GAAP EPS of $(0.07), surpassing the $(0.10) estimate. Sales reached $20.92M, exceeding the $20.74M forecast but marking an 8.86% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:02 pm

EDIT

Editas Medicine (NASDAQ:EDIT) reported Q4 earnings with a per-share loss of $(0.23), surpassing the $(0.54) estimate, marking a significant improvement from last year's $(0.88) loss. Quarterly sales reached $60.05M, greatly exceeding the $7.94M forecast and showing an 818.76% increase from the previous year's $6.54M. The company's cash and equivalents stand at $427.1M.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:02 pm

SRCL

Stericycle (NASDAQ:SRCL) reported Q4 adjusted EPS of $0.54, surpassing the $0.47 estimate, but its sales of $652M fell short of the $657.93M forecast. This represents a 10% decrease in earnings and a 2.74% drop in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:02 pm

MRSN

Mersana Therapeutics (NASDAQ:MRSN) reported Q4 earnings with EPS of $(0.16), meeting analyst estimates but with a 63.64% improvement over the previous year. However, their sales of $10.70M fell short of the expected $14.77M, marking a 27.55% miss and a 27.14% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:02 pm

PDCO

Patterson Cos (NASDAQ:PDCO) reported Q3 adjusted EPS of $0.59, missing the consensus estimate of $0.60, and sales of $1.62B, below the $1.63B estimate. This represents a 4.84% decrease in EPS and a 0.94% increase in sales year-over-year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:02 pm